ExceleraRx, a national specialty pharmacy network, last week named James Fox as its president and CEO, effective Sept. 1.
GlaxoSmithKline announced that the Food and Drug Administration approved its supplemental new drug application for Promacta (eltrombopag), a once-daily medication for patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.
A new report is shining a light on a key role pharmacists can play in helping patients understand the medicine they’re taking.
ViiV Healthcare announced that the Food and Drug Administration has approved Triumeq (abacavir 600 mg, dolutegravir 50 mg and lamivudine 300 mg) tablets for the treatment of HIV-1 infection.
Biotech company Roche will be acquiring research and pharmaceutical company InterMune for $8.3 billion, it announced over the weekend.
With the National Association of Chain Drug Stores Total Store Expo currently underway in Boston, the Boston Globe published an op-ed in its opinion section, Podium, which was co-authored by Steven Anderson, president and CEO of NACDS and Michael Malloy, PharmD and dean of the MCPHS University School of Pharmacy - Worcester/Manchester.
Specialty pharmaceutical company Mallinckrodt announced two new members to its leadership team following its recent acquisition of Questcor.
“All providers in the healthcare system should practice to the fullest extent allowed by their license.”
In July, the National Association of Specialty Pharmacy and the Specialty Pharmacy Association of America announced the two organizations would merge, creating the largest professional and trade association in the specialty pharmacy industry. To find out more, DSN interviewed Larry Irene, CEO of Armada Health Care and SPAARx founder, and Gary Cohen, CEO of NASP.
The Food and Drug Administration has approved Cerdelga (eliglustat) for the treatment of adult patients with the Type 1 form of Gaucher disease.